Wedbush Downgrades Meridian Biosciences (VIVO) to Underperform; Larger Challenges in Small Hospitals

Wedbush downgraded Meridian Biosciences (NASDAQ: VIVO) from Neutral to Underperform, price target cut from $16 to $14.

Wedbush analyst highlighted points include: 1) High probability of significant VIVO misses and 2012 guidance reset; 2) Cepheid's (Nasdaq: CPHD) growing strength in small hospitals represents a more serious obstacle to VIVO’s Illumigene growth; 3) Implied back half acceleration seems unreasonable given VIVO’s recent track record and susceptibility to EU or other macro regression; and 4) Continued 4.5% dividend yield is not enough to offset future earnings misses.

For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.

Shares of Meridian Biosciences closed at $17.29 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy